Warning Letters As Public “Leverage” Should Prompt GMP Compliance – Troy
This article was originally published in The Gray Sheet
Executive Summary
FDA Chief Counsel Daniel Troy emphasized the integral value of warning letters as public notification to a company's customers and competitors in a recent address to the University of Georgia's annual GMP conference